Anagenics Ltd
ASX:AN1
Intrinsic Value
Anagenics Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases o... [ Read More ]
The intrinsic value of one AN1 stock under the Base Case scenario is 0.019 AUD. Compared to the current market price of 0.009 AUD, Anagenics Ltd is Undervalued by 53%.
Valuation Backtest
Anagenics Ltd
Run backtest to discover the historical profit from buying and selling AN1 stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Anagenics Ltd
Current Assets | 5.4m |
Cash & Short-Term Investments | 1.3m |
Receivables | 709k |
Other Current Assets | 3.4m |
Non-Current Assets | 5.9m |
PP&E | 1.2m |
Intangibles | 4.7m |
Current Liabilities | 3.8m |
Accounts Payable | 2.7m |
Accrued Liabilities | 181.7k |
Other Current Liabilities | 930.3k |
Non-Current Liabilities | 381.3k |
Long-Term Debt | 341.6k |
Other Non-Current Liabilities | 39.8k |
Earnings Waterfall
Anagenics Ltd
Revenue
|
10.2m
AUD
|
Cost of Revenue
|
-5.4m
AUD
|
Gross Profit
|
4.7m
AUD
|
Operating Expenses
|
-7.3m
AUD
|
Operating Income
|
-2.5m
AUD
|
Other Expenses
|
-643.8k
AUD
|
Net Income
|
-3.2m
AUD
|
Free Cash Flow Analysis
Anagenics Ltd
AN1 Profitability Score
Profitability Due Diligence
Anagenics Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Anagenics Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
AN1 Solvency Score
Solvency Due Diligence
Anagenics Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Anagenics Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AN1 Price Targets Summary
Anagenics Ltd
Shareholder Return
AN1 Price
Anagenics Ltd
Average Annual Return | -35.09% |
Standard Deviation of Annual Returns | 30.44% |
Max Drawdown | -97% |
Market Capitalization | 3.8m AUD |
Shares Outstanding | 419 132 992 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Anagenics Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-12-09. The principal activities of the Company include the development, distribution and sale of health, beauty and wellness products (Consumer health). The firm through its wholly owned subsidiary Advangen Pty Ltd, develops, manufactures, markets, distributes to retailers, and sells its anti-aging products globally, with its FGF5 inhibitor, hair health and hair growth products. The flagship anti-aging hair care range, marketed as evolis, Advangen Jo-Ju, and Lexilis brands are sold in Australia, Japan, and the United States of America. The Company’s subsidiary is BLC Cosmetics Pty Limited, which is the distributor of premium Australian and international beauty and wellness brands, primarily to salons and spas.
Contact
IPO
Employees
Officers
The intrinsic value of one AN1 stock under the Base Case scenario is 0.019 AUD.
Compared to the current market price of 0.009 AUD, Anagenics Ltd is Undervalued by 53%.